The chemical structures of the lipids used for classic vaccines are seen to the right. Both of these lipids are endogenous and are metabolized by the normal biochemical pathways available in every cell of your body.

The pre clinical efficacy after nasal vaccination of the Eurocine™-adjuvant for classic vaccines has been demonstrated in reformulations with already existing influenza, diphtheria, tetanus and tuberculosis vaccines using nasal administration.

Eurocine has conducted its first clinical phase I trial with a nasal diphtheria vaccine.